DDM:ARCA-ProShares Ultra Dow30

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 49.01

Change

-0.95 (-1.90)%

Market Cap

USD 0.24B

Volume

0.49M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones Industrial AverageSM. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a price-weighted index and includes 30 large-cap, "blue-chip" U.S. stocks, excluding utility and transportation companies. The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: DJ Industrial Average TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.0%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
CVE Cenovus Energy Inc 3.45 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing DDM

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.59% 74% C 84% B
Dividend Return 0.52% 18% F 7% C-
Total Return 30.11% 74% C 82% B
Trailing 12 Months  
Capital Gain 8.21% 58% F 65% D
Dividend Return 0.62% 12% F 7% C-
Total Return 8.83% 58% F 59% D-
Trailing 5 Years  
Capital Gain 159.15% 94% A 94% A
Dividend Return 7.68% 87% B+ 25% F
Total Return 166.83% 94% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 22.55% 95% A 93% A
Dividend Return 23.65% 95% A 93% A
Total Return 1.10% 65% D 25% F
Risk Return Profile  
Volatility (Standard Deviation) 23.87% 26% F 28% F
Risk Adjusted Return 99.09% 87% B+ 89% A-
Market Capitalization 0.24B 89% A- 40% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.